However, despite the apparent need for more automation in diabetes therapy, only the HCL Medtronic MinimedTM 670G, as the world’s first insulin pump with adaptive basal insulin delivery, has become marketable thus far, and eligible for reimbursement in Germany in September 2019 [33]. This evidence concerns the gene INS and diabetes mellitus.